BB Biotech (BION) Stock Overview
An equity fund launched and managed by Bellevue Asset Management AG. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
BION Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
BB Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 42.85 |
| 52 Week High | CHF 49.65 |
| 52 Week Low | CHF 24.35 |
| Beta | 0.69 |
| 1 Month Change | -7.75% |
| 3 Month Change | -5.93% |
| 1 Year Change | 32.05% |
| 3 Year Change | -14.47% |
| 5 Year Change | -46.77% |
| Change since IPO | 395.95% |
Recent News & Updates
Late Stage Biotech Focus And M&A Tailwinds Will Support Long Term Portfolio Outcomes
Catalysts About BB Biotech BB Biotech invests in a concentrated portfolio of biotech companies with a focus on late stage clinical and early commercial assets. What are the underlying business or industry changes driving this perspective?
Patent Cliff Demand And Rate Volatility Will Pressure Biotech Portfolio Fundamentals
Catalysts About BB Biotech BB Biotech is an investment company that builds and manages a concentrated portfolio of biotechnology stocks with a focus on late stage clinical and early commercial companies. What are the underlying business or industry changes driving this perspective?Recent updates
Late Stage Biotech Focus And M&A Tailwinds Will Support Long Term Portfolio Outcomes
Catalysts About BB Biotech BB Biotech invests in a concentrated portfolio of biotech companies with a focus on late stage clinical and early commercial assets. What are the underlying business or industry changes driving this perspective?Patent Cliff Demand And Rate Volatility Will Pressure Biotech Portfolio Fundamentals
Catalysts About BB Biotech BB Biotech is an investment company that builds and manages a concentrated portfolio of biotechnology stocks with a focus on late stage clinical and early commercial companies. What are the underlying business or industry changes driving this perspective?Shareholder Returns
| BION | CH Capital Markets | CH Market | |
|---|---|---|---|
| 7D | -7.0% | -2.0% | -3.9% |
| 1Y | 32.0% | -9.5% | -4.2% |
Return vs Industry: BION exceeded the Swiss Capital Markets industry which returned -9.5% over the past year.
Return vs Market: BION exceeded the Swiss Market which returned -4.2% over the past year.
Price Volatility
| BION volatility | |
|---|---|
| BION Average Weekly Movement | 4.4% |
| Capital Markets Industry Average Movement | 3.8% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in CH Market | 7.8% |
| 10% least volatile stocks in CH Market | 2.3% |
Stable Share Price: BION has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: BION's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 10 | n/a | www.bbbiotech.ch/en/bb-biotech/ |
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.
BB Biotech AG Fundamentals Summary
| BION fundamental statistics | |
|---|---|
| Market cap | CHF 2.36b |
| Earnings (TTM) | CHF 578.13m |
| Revenue (TTM) | CHF 615.46m |
Is BION overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BION income statement (TTM) | |
|---|---|
| Revenue | CHF 615.46m |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 615.46m |
| Other Expenses | CHF 37.33m |
| Earnings | CHF 578.13m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 24, 2026
| Earnings per share (EPS) | 10.48 |
| Gross Margin | 100.00% |
| Net Profit Margin | 93.93% |
| Debt/Equity Ratio | 0% |
How did BION perform over the long term?
See historical performance and comparisonDividends
Does BION pay a reliable dividends?
See BION dividend history and benchmarks| BB Biotech dividend dates | |
|---|---|
| Ex Dividend Date | Mar 23 2026 |
| Dividend Pay Date | Mar 25 2026 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 1 day |
Does BION pay a reliable dividends?
See BION dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/23 23:23 |
| End of Day Share Price | 2026/03/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BB Biotech AG is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rene Rückert | Baader Helvea Equity Research |
| Thomas Meyer | Baader Helvea Equity Research |
| Falko Friedrichs | Deutsche Bank |